FDA Fast Track designation was supported by data from a Phase 2 study reviewing pamrevlumab in combination with gemcitabine and nab-paclitaxel.
Sexual impairment is frequently associated with breast and pelvic cancers, but patients with digestive cancer also experience this effect. In this study, researchers assessed sexual activity, dysfunction, sexual quality of life, and need for oncosexology care among patients with gastrointestinal cancers.
A multivariable analysis revealed how median household income influences cancer-specific and overall survival among patients with squamous cell carcinoma of the anus.
At $225 million per system, the precision of proton beam radiotherapy is not necessarily overshadowing its high costs. Yet ongoing studies seek to determine how this technology fits into current treatment regimens for prostate, breast, and other cancers.
Double-blind phase 3 study evaluated the effect of megestrol combined with celecoxib vs monotherapy on cachexia in patients with gastrointestinal cancer.
Those with pancreatic adenocarcinoma and a personal history of another cancer associated with hereditary breast and ovarian cancer or Lynch syndrome may be more likely to carry germline mutations.
1. Hot tea consumption in combination with excessive smoking or alcohol use was associated with a higher risk for esophageal cancer. 2. In the absence of excessive alcohol use and smoking, daily tea drinking was not linked to increased risk for esophageal cancer. Evidence Rating Level: 1 (Excellent) Study Rundown: Esophageal cancer is a concern 
Researchers conducted a retrospective study of US patients with gastric cancer to determine what factors influenced the use of preoperative chemotherapy in this patient population.
Comparative Study of Clinical Efficacy Using Three-dimensional and Two-dimensional Laparoscopies in the Treatment of Distal Gastric Cancer
[OncoTargets and Therapy] This study investigated the safety and feasibility of 3D laparoscopic-assisted radical gastrectomy for distal advanced gastric cancer vs 2D laparoscopic surgery, results of this study have shown.
Analysis revealed factors that contribute to reduced dietary intake among hospitalized patients with colorectal cancer.
[Cancer Management and Research] Radiation dose, fractionation strategies, and predictive factors of response to therapy in patients with esophageal carcinoma are reviewed to determine if more intense local therapy would lead to better outcomes and for which patients.
Safety and efficacy of atezolizumab with cobimetinib for heavily pretreated metastatic CRC was demonstrated in a phase 1b study that was presented at the 2018 Gastrointestinal Cancers Symposium.
Study results presented at the 2018 Gastrointestinal Cancers Symposium demonstrated the sensitivity and specificity of the CMx biomimetic platform, a novel approach to detecting CRC and precancerous lesions that could improve screening rates.
Results of the double-blind phase 3 CELESTIAL study, presented at the 2018 Gastrointestinal Cancers Symposium, demonstrated efficacy of cabozantinib in patients with HCC who were previously treated with sorafenib.
In a phase 3 study presented at the 2018 Gastrointestinal Cancers Symposium, researchers reported on OS outcomes with gemcitabine plus S-1 vs gemcitabine plus cisplatin in patients with advanced biliary tract cancer.
Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
[Journal of Thoracic Disease] A randomized study investigated whether an mERAS protocol could result in improved recovery of aged patients with esophageal cancer undergoing esophagectomy.
Data presented at the 2018 Gastrointestinal Cancers Symposium compared overall survival with cytoreductive surgery (CRS) alone for patients with gastric cancer and peritoneal carcinomatosis vs treatment with HIPEC plus CRS.
Research presented at the 2018 Gastrointestinal Cancers Symposium described benefits seen with RAMIE vs chemotherapy or chemoradiotherapy plus OTE for esophageal cancer.
Capecitabine and Oxaliplatin as First and Second Line Treatment for Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma
[Journal of Gastrointestinal Oncology] This research evaluates the use of capecitabine and oxaliplatin (CAPOX) for first or second-line treatment of locally advanced or metastatic PDAC.
Ogivri was granted FDA approval to treat HER2 breast and gastric or gastroesophageal junction adenocarcinoma cancers.
Periodontal pathogen Tannerella forsythia linked to increased risk of esophageal adenocarcinoma
Increased risk seen in H. pylori-infected subjects who received eradication therapy
A cross-sectional survey revealed the impact of symptoms and economic burden on quality of life for survivors of gastrointestinal cancer.
Utilization and Trends in Palliative Therapy for Stage IV Pancreatic Adenocarcinoma Patients: A U.S. Population-based Study
[Journal of Gastrointestinal Oncology] This research examined patients who presented with metastatic pancreatic adenocarcinoma at diagnosis, and their patterns of palliative care utilization.
Researchers think chronic inflammation in gastrointestinal tract may increase the future risk of gastrointestinal cancers, lymphoid neoplasms, and skin cancer.
An association was found between low PNI/high CAR levels and poor outcomes in operable pancreatic ductal adenocarcinoma, even in patients who undergo curative resection.
A study on a cohort of women enrolled in the WHI-OS shows that those with a history of periodontal disease had a higher risk for developing some cancers.
A new report from ACS describes trends in liver cancer and the factors influencing the ongoing increase in incidence, particularly higher rates of HCV infection, obesity, and type 2 diabetes.
By identifying incidence, prevalence, and risk factors for colorectal and pancreatic cancer in our communities, nurse navigators can develop screening and prevention programs to better serve these populations.
Study compared FOLFOXIRI/bevacizumab and FOLFOX/bevacizumab in patients with metastatic colorectal cancer.
Patients with stage III colon cancer who follow the ACS guidelines for a healthy lifestyle after adjuvant chemotherapy had longer disease-free survival and overall survival.
Consumption of tree nuts is associated with significantly improved disease-free survival (DFS) and overall survival (OS) in survivors of stage III colon cancer who consume 2 or more servings per week.
Precision Medicine Improves Pancreatic Cancer Treatment
Cisplatin plus standard-of-care gemcitabine/nab-paclitaxel improved tumor shrinkage in patients with metastatic pancreatic cancer, according to a study by the HonorHealth Research Institute and the Translational Genomics Research Institute.
Biopolymer codelivery of CAR T cells and stimulator of IFN genes directly to the surface of solid tumors more effectively reduced tumor size.
Trends in SEER data from 1972 to 2009 show gallbladder cancer incidence decreasing in men, but late-stage disease at diagnosis for both sexes is increasing.
Although median survival is longer for Hispanic and black patients compared with white patients, health-related QoL is poor for minority patients.
Decreased liver tumor growth and improved survival in a mouse model were noted after injecting iPS-ML/IFN-β.
Exercise helps patients with gastrointestinal cancer undergoing chemotherapy cope with their disease and treatment.
ACS colorectal cancer statistics show an overall decrease in incidence due to increases in screening rates; however, age-related incidence is trending up in younger persons, down in older persons.
A phase 3 analysis of SWOG Intergroup Trial S0033 reveals that imatinib significantly extends survival in patients with GIST.
Outcomes improved with short-course radiation and delay to surgery of 4 to 8 weeks.
Women with poor metabolic health have a greater risk of colorectal cancer than those with increased weight.
Clinical trials show pembrolizumab active against mucosal melanoma, extends survival in bladder cancer.
An investigation into whether onset or worsening of diabetes causes pancreatic cancer or vice versa was presented at the 2017 European Cancer Congress.
Research presented at the 2017 European Cancer Congress describes the potential of a noninvasive diagnostic test for esophageal and gastric cancers that measures chemicals in the breath.
Use of Adjuvant gemcitabine plus capecitabine for patients with pancreatic cancer who have undergone tumor resection resulted in a modest increase short-term survival.
Chemotherapy may be overused among young and middle-aged adults with colon cancer, with the addition of adjuvant chemotherapy not resulting in a matched survival benefit.
Researchers reveal that miR-17 appears to be important in driving esophageal tumor resistance to radiotherapy.
PDX1 appears to have distinct roles at different stages of pancreatic cancer development.
Researchers conduct a retrospective cohort study of histologically diagnosed gastrointestinal stromal tumors in the Surveillance, Epidemiology, and End Results (SEER) database.
Researchers have found that hepatitis C virus infection is associated with an elevated risk for developing bile duct cancers and diffuse large B-cell lymphoma.
In a phase 3 trial, researchers determined if weekly nab-paclitaxel was noninferior to weekly solvent-based paclitaxel with respect to overall survival in patients requiring second-line treatment for advanced gastric cancer.
Findings are presented from an open-label NETTER-1 clinical trial evaluating the efficacy and safety of 177Lu-Dotatate in patients with advanced midgut neuroendocrine tumors who have experienced disease progression during first-line treatment with a somatostatin analogue.
Drug-drug interaction between capecitabine and common heartburn medications has a negative effect on progression-free survival and overall survival in patients with GI cancer.
Given the frequency of gene mutations in patients with early-onset CRC, genetic counseling and testing could be considered for this population.
Seluminitinib in combination with an AKT inhibitor did not improve survival compared with modified FOLFOX in previously treated metastatic pancreatic cancer.
Adding the mesenchymal-epithelial transition (MET) antibody onartuzumab did not significantly improve clinical outcomes.
Survey data from patients receiving care at Boston Medical Center who were navigated for colonoscopy screening illustrates how patients value the services of oncology patient navigators.
A possible association between moderate to heavy alcohol consumption has been shown in previous studies. In this study, investigators examined the relationship between alcohol consumption and colorectal cancer survival remains unclear.
A retrospective evaluation investigated the association between risk of esophageal cancer, metabolic syndrome, Barrett esophagus, and GERD in older persons.
In this study, the impact of advancements in surgical technique and systemic therapy for stage II and III rectal cancers was assessed via a comparison of outcomes after neoadjuvant chemoradiotherapy followed by definitive resection with those for neoadjuvant multiagent chemotherapy without radiation therapy.
Smoking-attributable cancer mortality estimates have not been established by state; therefore, in this study, the proportion of cancer deaths among persons 35 years and older related to cigarette smoking in 2014 was calculated for each state and DC.
Novel preparation formulation is as effective and safe as current colon prep for colonoscopy. Plus, study participants gave the prep experience a high satisfaction rating.
Because gastric acid suppressants, such as proton pump inhibitors, affect the absorption of some oral cancer medications, researchers sought to determine if proton pump inhibitors impair capecitabine efficacy.
A review of adverse effects and recommended management for 3 kinase inhibitors indicated for the treatment of gastrointestinal cancers.
What is the interaction between oral chemotherapy and GERD medicines?
Adding rolapitant to a 5-HT3 receptor antagonist and dexamethasone significantly improved the prevention of CINV in patients with GI and CRC cancers receiving highly or moderately emetogenic chemotherapy.
[Journal of Gastrointestinal Oncology] This research examines factors associated with survival in patients with brain metastasis from esophageal cancer.
Applying evolutionary theory improves the accuracy of predicting in which patients Barrett's esophagus will progress to esophageal adenocarcinoma.
Lifestyle and dietary measures for preventing colorectal cancer are extensively studied; however, in this study, researchers looked at a dietary measure that improved survival for patients after diagnosis.
Poor compliance to NCCN guidelines for adjuvant chemotherapy appears to be associated with poorer overall survival.
Favorable Perioperative Outcomes After Resection of Borderline Resectable Pancreatic Cancer Treated With Neoadjuvant Stereotactic Radiation and Chemotherapy Compared with Upfront Pancreatectomy for Resectable Cancer
[Journal of Gastrointestinal Oncology] This research examines outcomes related to the use of neoadjuvant multi-agent chemotherapy and stereotactic body radiation therapy (SBRT) in borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC) patients.
Research indicates that metformin can confer improved survival for patients with colorectal cancer that also have diabetes.
Research findings reveal the mechanism by which obesity increases inflammation and desmoplasia in the most frequent type of pancreatic cancer, using mouse models and human tissue samples.
Systematic Palliative Care Provides Greater Improvement in Quality of Life for Patients with Pancreatic Cancer
Quality of life is significantly improved for patients with pancreatic cancer when systematic palliative care is administered vs on-demand palliative care.
Genetic biomarkers from tumor DNA circulating in the bloodstream could indicate the risk for recurrence of colorectal cancer and the efficacy of chemotherapy after surgery.
The multikinase inhibitor regorafenib significantly improved overall survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase 3 RESORCE trial.
Adjuvant chemotherapy is associated with improved overall survival in patients with stage II colon cancer regardless of treatment regimen, patient age, or high-risk pathologic risk features.
Using a computer algorithm to scan images of the esophagus for signs of early esophageal cancer is nearly as accurate as top specialists.
The proportion of older patients with comorbidities receiving treatment for metastatic colorectal cancer (mCRC) has increased over the last 2 decades despite the overall percentage of older adults being treated remaining low.
Drinking scalding coffee, tea, or yerba mate might increase the risk of developing esophageal cancer according to the World Health Organization. Beverages hotter than 149°F (65°C) might increase the risk of developing esophageal cancer.
Aspirin's anti-inflammatory action is protective against another aggressive cancer: cholangiocarcinoma. Furthermore, it is beneficial regardless of daily use or dose.
[Clinical Medicine Insights: Oncology] This research examines the role of adjuvant chemotherapy in resectable bile duct cancer treatment.
Metastatic capabilities of pancreatic cancer might arise before tumors even form. Metastasis and advanced stage of disease at diagnosis are attributed to low survival rates for pancreatic cancer.
Measurements of copies of a single gene circulating in the bloodstream allowed scientists to identify patients with stomach cancer who were most likely to respond to treatment.
Combining a laboratory ultrasound technique called sonoporation with the commercially available chemotherapy compound gemcitabine increases the porosity of pancreatic cells with microbubbles and helps get the drug into cancer cells.
Despite the increased risk, patients whose pancreatic cancer tumor has grown to encompass critical blood vessels can be candidates for surgery. Data on efforts to fine-tune a protocol for these patients were presented at the SSAT 57th Annual Meeting.
Adjuvant gemcitabine plus capecitabine significantly improved overall survival compared with gemcitabine monotherapy in patients with pancreatic ductal adenocarcinoma, according to results of the ESPAC-4 trial presented at the ASCO 2016 Annual Meeting.
First results from the phase 3 CRITICS study found no significant difference in overall survival between postoperative chemotherapy and chemoradiotherapy in patients with resectable gastric cancer, according to a study presented at the ASCO 2016 Annual Meeting.
A study of nearly 1000 patients with HCC found that black patients with the disease had a 33% greater risk of death compared with non-Hispanic whites.
Chemoradiotherapy Showed No Survival Benefit Over Chemotherapy in Locally Advanced Pancreatic Cancer
Researchers discovered no survival benefit of chemoradiotherapy over chemotherapy in treating locally advanced pancreatic cancer in the LAP01 Randomized Clinical Trial.
Barriers to Understanding Pancreatic Cancer Can Be Overcome With Improvements to Online Health Information
Available information on pancreatic cancer was written at too high a level and contained inaccuracies regarding alternative therapies, a recent study has shown.
Molecular profiling of a case of advanced pancreatic cancer identifies an active and tolerable combination of targeted therapy with backbone chemotherapy
[Journal of Gastrointestinal Oncology] This research reviews the case history of a patient with stage IVB pancreatic adenocarcinoma initially treated with gemcitabine and erlotinib who stopped therapy after 3 months without achieving a response and was switched to a different and effective combination strategy.
A small molecule that inhibits RAS protein interactions offers hope for targeting this elusive protein. It is one of the most sought-after cancer targets for drug developers, but the mutant RAS protein lacks drug-binding pockets.
People who took aspirin on a regular basis were three times less likely to develop the disease.
Lowest accuracy scores for alternative tx websites; websites with higher accuracy more difficult to read
Incorporating a modified MASCC grading tool for evaluating epidermal growth factor receptor inhibitor (EGFRI) toxicities and quality of life improved the rate of skin assessments and documentation.
Oncology nurses are in an ideal position to educate patients with gastrointestinal malignancies and PVT about risk factors, clinical presentation, complications, and treatment options to prevent further extension of the clot.
Clinical trial results are promising for the use of nivolumab to treat squamous cell carcinoma of the anal canal, according to data presented at the 2016 American Association for Cancer Research Annual Meeting.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
- Patient Fears of Placebo Use in Clinical Trials
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|